Pediatric cranio-spinal axis irradiation (CSI) is a valuable treatment for many central nervous system (CNS) diseases, but due to the life expectancies and quality of life expectations for children, the minimization of the risk for radiation-induced secondary malignancies must be a high priority. This study compared the estimated CSI-induced secondary malignancy risks of three radiation therapy modalities using three different models. Twenty-four (n 5 24) pediatric patients previously treated with CSI for tumors of the CNS were planned using three different treatment modalities: three-dimensional conformal radiation therapy (3D-CRT), volume modulated arc therapy (VMAT), and Tomotherapy. Each plan was designed to deliver 23.4 Gy (1.8 Gy/fraction) to the target which was defined as the entire brain and spinal column with a 0.7 cm expansion. The mean doses as well as the dose volume histograms (DVH) of specific organs were analyzed for secondary malignancy risk according to three different methods: the effective dose equivalent (EDE), the excess relative risk (ERR), and the linear quadratic (LQ) models. Using the EDE model, the average secondary risk was highest for the 3D-CRT plans (37.60%), compared to VMAT (28.05%) and Tomotherapy (27.90%). The ERR model showed similarly that the 3D-CRT plans had considerably higher risk (10.84%) than VMAT and Tomotherapy, which showed almost equal risks (7.05 and 7.07%, respectively). The LQ model requires organ-specific cell survival parameters, which for the lungs, heart, and breast relevant values were found and applied. The lung risk for secondary malignancy was found to be 1.00, 1.96, and 2.07% for 3D-CRT, VMAT, and Tomotherapy, respectively. The secondary cancer risk for breast was estimated to be 0.09, 0.21, and 0.27% and for heart it was 9.75, 6.02 and 6.29% for 3D-CRT, VMAT, and Tomotherapy, respectively. Based on three methods of secondary malignancy estimation, the 3D-CRT plans produced highest radiationinduced secondary malignancy risk, and the VMAT and Tomotherapy plans had nearly equal risk. Pediatric patients must be treated with reducing long term sequelae as a priority.
Introduction
Cranio-spinal axis irradiation (CSI) is used to treat tumors of the central nervous system (CNS) and usually irradiates the entire brain and spinal cord of the Technology in Cancer Research & Treatment 2014 March 28. Epub ahead of print patient. In pediatric patients in the age range 0-19 years, CNS tumors contribute up to 25% of all the cancer malignancies that affect this population (1) . Utilizing CSI as part of the method to treat children with CNS diseases (the majority of which are medulloblastomas) can offer a five-year survival rate of greater than 80% (2, 3) . A downside of the therapy is caused by the large volume being irradiated, which results in the delivery of significant doses to many normal tissues and critical organs during the treatment (4, 5) . Increased radiation doses to normal tissues have been shown to cause secondary malignancies, which occur later in life for those treated (6) (7) (8) (9) , and therefore this issue is also of great concern for pediatric patients. Because it is expected that pediatric patients should have long life expectancies in contrast to more elderly cancer patients, the long-term quality of life and risk of secondary malignancies must be thoroughly estimated and be taken into account during treatment planning.
For CSI patients treated with a multi-discipline approach of chemotherapy and radiation therapy in particular, long-term sequelae include: endocrine effects, hearing and/or vision loss, gonadal dysfunction, neurocognitive deficits, cardiopulmonary impairment, and secondary malignancies (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Pediatric cases have been given special attention regarding the risk for secondary malignancies following radiation therapy after the publication of data indicating an increase in the development of these malignancies in persons irradiated at younger ages (21, 22) .
As a result of recent advances in technology, intensity modulated radiation therapy (IMRT) modalities are now used to treat many different treatment sites. A benefit of IMRT includes greater conformity of the dose to the prescribed target area which can help in the limitation of the dose to the surrounding normal tissues (23) (24) (25) (26) (27) (28) (29) . However, due to the higher number of monitor units (MU) and greater number of fields needed for the more complicated delivery of IMRT, larger areas of normal tissues are usually exposed to low levels of radiation (30) . In contrast, three dimensional conformal radiation therapy (3D-CRT) deliveries avoid this increase in low level periphery dose by using less MU and consisting of more open, static treatment fields. The choice of which technique to use for CSI pediatric patients must be made not only on the basis of better dosimetric conformality, but also on the technique which will attribute fewer long-term complications, including secondary malignancies, for the patients.
While the subject of radiation-induced secondary malignancy risk has been reported in the literature (6) (7) (8) (9) 31) , there is still very limited, conclusive data on these risks for patients undergoing CSI treatments using different modalities of radiation delivery as well as for pediatric patients in particular. There are a few studies, which have been conducted focusing on these secondary malignancy risks for pediatric patients treated with CSI therapy (10, (32) (33) (34) (35) (36) . However, these studies mainly consist of a small number of patients and many of the studies focus on the use of proton therapy for CSI. While proton therapy has proven to be a valuable technique for CSI treatment and reduction of secondary malignancies, this technology is not readily available to all clinics at this time. Furthermore, the comparison in our work uses three widely applied treatment modalities for a comparison that has not been done previously. Additionally, this study focuses on a wide pediatric age range with many more patients than those used in previous reports. Also, according to the results of previous publications, there are contradicting findings reported about which modality can best reduce the risk for secondary malignancies. While most of the data does validate the decreased risk using proton therapy, different studies have found that traditional 3D-CRT modalities have lower risks than the more advanced IMRT modalities (10, 33) , whereas others have reported the opposite as a conclusion (32, 34) , who used higher prescription doses (36 Gy) . The results of this work may provide new information on the debate for the use of conventional and newer technologies in radiation therapy of childhood CSI.
This study aimed to compare three different treatment modalities, including 3D-CRT and two IMRT modalities (volumetric modulated arc therapy, or more specifically SmartArc for this study, and Helical Tomotherapy) based on their risks for inducing secondary malignancies after treatment. Knowing which modality will provide the lowest risk to the treated children will allow the optimization of the therapy of pediatric patients in order to have a better quality of life long after the completion of their treatments. Using three different models for estimating these secondary cancer risks, this study generated essential knowledge for providing pediatric patients with the highest probability of minimizing their risk of developing a secondary malignancy as a result of their initial radiation therapy. This manuscript conducted a relative risk comparison study for secondary malignancy risk as it pertains to a pediatric population between three treatment modalities.
Materials and Methods

Treatment Setup, Prescription and Modalities
Twenty-four (n 5 24) pediatric patients (defined as those being under 20 years of age during treatment) previously treated with CSI for tumors of the CNS were retrospectively planned using three different radiation therapy modalities: three-dimensional conformal radiation therapy (3D-CRT), SmartArc (SA) volumetric modulated arc therapy (VMAT), and helical tomotherapy (HT). Each plan was designed to deliver 23.4 Gy to the planning target volume (PTV), which consisted of the entire brain and spinal column with a 0.7 cm expansion. The organs at risk (OAR) were contoured on each patient's CT image set and the doses to those structures were determined. Those structures included: right and left lungs, right and left kidneys, right and left orbits, thyroid, colon, heart, liver, and right and left breasts for female patients. Fractions of 1.8 Gy were prescribed to a total number of 13 fractions for each plan. The different plans were optimized to meet the acceptance criteria according to which at least 95% of the volume of the PTV should receive the prescribed dose (37) . A single planner designed, evaluated, and completed each of the plans for all the modalities involved according to institutional policies for purposes of consistency. The planning criteria for the target and the organs at risk were set by a single physician and they were used to develop optimal treatment plans for each patient and treatment modality examined.
3D-CRT Treatment Planning
The 3D-CRT treatment plans were produced using the Pinnacle 3 (Philips Medical, Fitchburg, WI) treatment planning system (TPS) with two lateral whole-brain fields and one posterior spinal field ( Figure 1 ). For this purpose, a Varian 21EX linear accelerator (Varian Medical Systems, Palo Alto, CA) equipped with 120 Millennium multileaf collimator (MLC) was employed. In order to protect the face of the patient, shielding blocks were created for each of the whole-brain fields. To avoid divergence of the cranial fields into the orbits of the patient a collimator rotation was utilized, and the "gap match" technique described by Khan was implemented at the site of the junction of the spinal and brain fields (38) .
Volumetric Modulated Arc Therapy Treatment Planning
The VMAT plans were produced using the same linear accelerator that was used for the 3D-CRT planning, and they were optimized with one superior and one inferior arc of 6 MV photons as shown in Figure 2 . The two arcs were designed to treat the patient with a gantry rotation from 1 to 359 degrees and gantry spacing of 4 degrees. The treatment was optimized to deliver the prescribed dose to 95% of the volume of the PTV along with other treatment objectives, which were used to minimize dose to the OARs (lungs, heart, kidneys, thyroid, colon, liver, orbits, and breasts for female patients). 
Helical Tomotherapy Treatment Planning
The HT plans were produced using the TomoTherapy Hi-Art (TomoTherapy Inc., Madison, WI) treatment unit and respective TPS. The parameters used by the TPS were a field width of 5.02 cm, 0.287 pitch, and a modulation factor of 2.0. Similar to the VMAT optimization, the HT plans were optimized to deliver the same level of prescription dose to the PTV while trying to attribute as low dose as possible to the OARs. In order to illustrate the dosimetric relation of the plans by the three treatment modalities, a comparison of the 3D-CRT, VMAT, and HT is presented in Figure 3 in terms of isodose line distribution in axial, coronal, and sagittal orthogonal planes. Furthermore, the dose volume histograms (DVHs) of the PTV and OARs are shown in Figure 4 for the different treatment modalities. Figures 3 and 4 display a dosimetric comparison between the three treatment techniques using a representative patient. Due to the consistency by which dose prescription and beam configuration were performed in all the patients, the presented dose distributions and DVHs have a small variation among the different patients for the same treatment technique.
Secondary Malignancy Risk Calculation Methods
In order to assess the radiation-induced secondary malignancy risks for the given patients and treatment modalities, the mean doses as well as the dose volume histograms (DVH) of each OAR were used. In each case, the risk for secondary malignancy was calculated according to three different methods: the mean organ dose calculation based on the effective dose equivalent (EDE), the mean organ dose calculation based on the excess relative risk (ERR), and the volumetric organ dose calculation based on the linear quadratic (LQ) model. 
The Effective Dose Equivalent Model
The first method used for evaluating the radiation-induced cancer risk after CSI was the EDE model. The mean dose for each of the studied organs at risk for each treatment method was determined. Equation [1] was then applied to calculate the EDE for whole-body dose estimation (39):
where EDE is the summation over all the organs of the product of the absorbed dose (mean dose to the given organ), W R is the radiation weighting factor (which is equal to unity in this case due to the fact that all the treatments were planned using photon energy of 6 MV), and W T is the tissue weighting factor (which has been determined for each OAR). Table I provides the W T factors used in this study according to the ICRP report (40, 41) .
After the determination of the EDE for each patient and treatment modality, the respective risks for secondary malignancy were calculated by multiplying the EDE with the factor of the ICRP recommendation for a 5% chance of secondary cancer occurrence per Sievert. This factor is valid for whole-body EDE both for the general population as well as children (40) .
The Excess Relative Risk Model
The second method for estimating the secondary malignancy risk from the examined CSI treatments, was the ERR model. The average ERR factors were taken from the Atomic Bomb Life Span Study for individuals under the age of 20 years at the time of exposure and are summarized in Table II ( 42) . Using these average ERR factors, the overall secondary malignancy risk was calculated by applying the following equation:
where the overall risk is the summation over all the organs at risk in this study.
The Linear Quadratic Model
The third method for secondary cancer risk estimation used in this study was the LQ model proposed by UNSCEAR (43, 44) . This model takes into account both the induction of DNA mutations and the component of cell survival within the cells that are irradiated. In the present study, the following equation, which is defined for a given fractionation scheme, was employed:
where v i indicates a given subvolume of the organ, α 1 , β 1 , α 2 , and β 2 are the cell survival parameters for the given organ at risk being evaluated with α 1 and β 1 pertaining to radiationinduced mutation parameters, whereas α 2 and β 2 are cell survival parameters. D is the total dose delivered in n fractions. The first term in Equation [3] represents the induction of DNA mutations, while the second term represents cell survival. The volumetric data was obtained from exporting the DVH information from both the Pinnacle and Tomotherapy TPS for the different radiation modalities.
In order to calculate the total risk for secondary malignancy, the entire DVH of each organ was utilized along with Equation [4] (43, 44) :
Table III summarizes the cell survival parameters found in the literature that were used for this study (43, (45) (46) (47) . DNA mutation and cell survival parameters are not widely known and have not been determined for all the organs used in this study. Previously published values were used to determine the secondary malignancy risks of lungs, heart, and breasts.
The cell response parameters for the lungs, heart, and breasts have been derived and applied to adult calculations in previous publications (43, (45) (46) (47) . It has been reported however, that overall, children are twice or even six times more sensitive to radiation-induced secondary malignancies compared to adults (7, 41) . It has been cited in literature that for breast cancer risk, pediatric females are up to 15 times more radiosensitive than older adults (39) . Taking these sensitivities into consideration, more appropriate, pediatric ageadjusted risks for the lungs and heart (assuming a two times higher radiosensitivity), as well as for the breasts (fifteen times higher radiosensitivity) were calculated for the patients in this study (Table VII) . This was done by using the α and β values of adults to calculate the effective radiosensitivity of the tissue, which was then rescaled to the one reported above and out of which the age-adjusted values of α and β were calculated. While this does not change the outcome of the relative comparison between the three treatment modalities, it gives more child-sensitive risk estimations for these organs.
Although a whole-body risk estimation was not calculated for the LQ model due to the lack of cell-response parameters, assessing the risks to these organs for which those parameters are known offers more information concerning a comparison between the three radiation modalities and therefore it still provides a valuable finding.
Results
The Effective Dose Equivalent Model On average, 3D-CRT plans had approximately a 10% higher overall secondary cancer risk than the VMAT and HT plans. This is due to the higher EDE whole-body doses calculated for the 3D-CRT plans. Using a paired t-test analysis (p , 0.05), it was found that the 3D-CRT EDE risk was statistically higher compared to VMAT (p 5 1.14e-06) and HT (p 5 6.48e-08). VMAT and HT plans were not found to have a statistically significant difference (p 5 0.74) based on the EDE model. The use of the 5% per Sievert risk factor is a conservative estimate and therefore leads to fairly high secondary malignancy risk estimations for all three cases as compared to the two other methods of analysis. While the absolute risk may be inflated by the use of this very conservative parameter, a relative comparison of the three techniques still provides helpful information concerning the lower estimated risk for the two IMRT modalities as opposed to using 3D-CRT. On average, the 3D-CRT plans showed approximately a 3.8% higher overall secondary cancer risk than the VMAT and HT plans using the ERR model. Similarly to the previous evaluation method, using a paired t-test analysis (p , 0.05), the 3D-CRT plans were found to produce a statistically significant increase in the risk for secondary malignancy as compared to the respective VMAT (p 5 1.02e-10) and HT (p 5 8.46e-12) plans while there was no statistical difference in the risks for secondary cancer between the VMAT and HT modalities (p 5 0.84).
The Excess Relative Risk Model
The Linear Quadratic Model
Using the DVH data of each patient and treatment modality together with the cell response parameters of the lungs, heart, and breasts (for females only), the respective secondary malignancy risks were calculated and are summarized in Table VI . The presented values have been averaged over all the patients in this study. Using the sensitivity adjustments previously discussed in the Methods and Materials section, Table VII shows the calculated risks using the LQ model that may be more appropriate by taking the radiosensitivity of children versus adults into consideration.
The breast and lung secondary cancer risk calculation showed a higher average risk for the VMAT and HT plans compared with the 3D-CRT modality. The estimation of the secondary risk for the heart showed a higher average risk for the 3D-CRT plans as compared to the two IMRT modalities. These findings are indicative of the treatment field setup for the different treatment modalities. Because the VMAT spinal field of the 3D-CRT plans and therefore it has a potential to receive a substantial amount of exit dose. This leads to the higher secondary risks for the heart by this technique. The lungs and breasts are situated more laterally in the patient than the central, 3D-CRT spinal field and therefore this field does not contribute significant doses to the total volume of these organs leading to lower secondary risks.
Discussion
Even though protons have become more prevalent in the treatment of CSI, most of the radiotherapy centers worldwide do not have access to proton facilities. For this reason, the present study focuses on the evaluation of CSI treatment using our "gold standard" of tomotherapy, 3D-CRT and the newer VMAT technology. Although there are a number of other techniques that have been proposed or applied (e.g., utilizing electron beam for irradiating the spinal axis in order to achieve normal tissue sparing comparable to protons), the most common techniques were employed here for the relevant analysis.
In the present study, for each patient, the three-dimensional dose distribution to each of the organs was available. However, due to the fact that in the EDE and ERR models the risk of secondary malignancy is linearly proportional to the dose, the mean dose to each individual organ was used.
Although statistically significant results were found for the EDE and ERR models, it should be pointed out that those results are based on the reference values of the different tissues (Tables I and II) , which are accompanied by confidence intervals, and a full sensitivity analysis would be more appropriate to establish such conclusions.
Age Analysis
For this study, the pediatric age group was characterized as CSI patients less than 20 years of age. The data for this manuscript was obtained with a diverse pediatric population of median age 10, ranging from 2 to 18 years of age, 11 females and 13 males, and a wide range of heights and weights in order to encompass many of the anatomical differences amongst the pediatric population as a whole. For further evaluation, patients were separated into age groups: 0-5 years (4 patients), 6-10 years (8 patients Overall, a trend was seen that the older the patient, the lower the secondary malignancy risk. As the age of the patient increases, the volumes of the different organs also get larger due to growth, which leads, on average, to lower mean doses to the whole organ at risk and lower risks for secondary and HT plans deliver dose from multiple angles around the patient, normal tissues outside the immediate treatment area will receive a smearing of lower doses. Due to its central location within the patient, the heart can be in the direct exiting Figure 5 : Comparison of the risk of secondary malignancy for 3D-CRT, HT, and SmartArc (SA) VMAT for lungs, heart, and breasts based on the respective estimates by the EDE, ERR, and LQ models. In these box-plots, the mean and median, 25% and 75% quartiles, and the maximum and minimum values are shown in every case. malignancies. The pattern of findings of the relative comparison between the treatment modalities remained the same for the different age groups still indicating a lower overall risk for the VMAT and HT as opposed to the 3D-CRT modality.
Organ-specific Analysis Figure 5 presents an organ-specific box-plot for the normal tissues that were common in all three risk calculation methods: lungs, heart, and breasts. These box-plots display the median of the 24 patient values (line through the middle of the boxes), mean (small square in the boxes), maximum and minimum values (stars above and below the boxes), and the spread of the data within 25-75% of the mean value (area encompassed by the box) for each treatment modality and each secondary malignancy calculation method for comparison. Comparing the three secondary malignancy risk models on an organ-specific basis revealed somewhat different trends than what had been reported by the overall, whole-body risk calculations. For example, using the EDE, ERR, and LQ models to calculate the risk for each of the three common organs, the results indicated that using the 3D-CRT modality would be the optimal technique for reducing secondary malignancy risk to the lungs. However, 3D-CRT would contribute the highest secondary malignancy risk to the heart as compared with the HT and VMAT modalities. This analysis also showed that HT is associated with the highest risk for secondary malignancy of the breasts. Figure 5 also indicates that overall, the ERR and LQ calculation models may be a more accurate and consistent means of calculation because they contain a narrower spread across the patient data as indicated by their thinner boxes and shorter distances between maximum and minimum data values, in general. This finding is in agreement with recent reports, which state that general risk models tend to overestimate secondary cancers compared to epidemiological studies of patients treated with radiation therapy (48) .
Comparison to Previously Published Studies
Several studies have been published concerning the risk of secondary malignancies after radiation of the cranio-spinal axis for patients with medulloblastoma using different combinations of treatment techniques and analysis methods (10, (32) (33) (34) (35) (36) . To compare the risks for secondary malignancy calculated in this study with those previously reported, the respective values from the 3D-CRT, HT, and VMAT treatment modalities were obtained. Miralbell et al. (32) concluded that the lifetime risk was approximately 54.8% and 31.4% for 3D-CRT and IMRT, respectively. Mu et al. (33) reported that the secondary lethal cancer risk for conventional photon therapy was about 20% and 30% for IMRT. Brodin et al. (10) reported lifetime risks using the organ equivalent dose method to be 45% for 3D-CRT and 56% for arc therapy, however, using a linear analysis method the arc therapy risk was found to be 33% versus 36% for 3D-CRT. Yoon et al. (36) reported qualitatively that tomotherapy produced secondary risks similar to those of IMRT and 3D-CRT. Compared to this data, our results from the analysis using the EDE model of secondary malignancy risk quantitatively agreed overall. Using the ERR method of analysis, the data reported in this study qualitatively agreed with that published by Miralbell (33) reported higher effective doses to the lungs and mammary glands after they compared IMRT versus 3D-CRT indicating a higher risk for these organs. The analysis based on the LQ model that was performed in this study for these organs (lungs and breasts) showed a quantitative and qualitative agreement with those studies as the risks for the lungs and breasts were found to be higher for the VMAT and HT modalities than those incurred for 3D-CRT. Overall, the results of this study agreed well with those that have been previously published for childhood CSI radiationinduced secondary malignancies.
Risks of second cancers are largely concentrated in areas of high dose gradients near field edges, i.e., 66% at edge of field, verses 12% in field and 22% out-of-field (49) . Thus, it is particularly important to clinically develop treatment plans of the highest quality and as conformal as possible. In this study, doses to organs that received both high and low doses are considered. It has been reported that commercial treatment planning systems (e.g., Pinnacle and Eclipse planning systems) underestimate very low doses (50, 51) . Furthermore, sometimes the organs under examination are not entirely encompassed within the dose calculation grid. Although this study is a relative comparison between three techniques and not an absolute determination of secondary malignancy risk, the calculation grid encompassed the entire patient CT and was kept consistent across all the plans and techniques so that the relative comparison could be most accurately performed. Additionally, although the size of the grid may influence the accuracy of dose calculation, in this work a high grid resolution was used in order to minimize the impact of those factors on our results.
In the manuscript the scaling factors are used merely as a representation of the increased importance of the differences between the risks of each treatment technique examined regarding pediatric patients. As it was stated previously, the values reported here do not serve for absolute pediatric risk comparisons, but for the purposes of this study they serve to show the impact of using the appropriate technique to minimize secondary malignancy risks as these can be critical for radiosensitive young patients. The determination of scaling factors for pediatric patients is still very uncertain. However, the values used, do not affect the relative comparison between the three treatment techniques that were examined.
Finally, it should be stated that due to the fact that the parameters or factors that are used to calculate the risk for secondary malignancies are characterized by large uncertainties, it is more proper to treat the findings of these studies and comparisons as well as of the present one as relative trends between the different radiation modalities that are compared rather than absolute expected values. In this sense, their relative optimization could be a useful feature in treatment planning and treatment technique comparisons.
Conclusion
According to the three calculation methods of secondary malignancy risk estimation, for the radiation modalities of VMAT and Helical Tomotherapy, the radiation-induced risk for secondary malignancies is minimized compared with the traditional 3D-CRT treatment modality. While the risk to the breasts and lungs was slightly lower for 3D-CRT according to the LQ model, on average the effective whole-body dose was higher and therefore the risk for secondary malignancy was increased. The risk estimates were seen to increase when considering younger, smaller patients since the overall risk was found to increase with decreasing age, and size of the patient. Special attention must be paid to the late outcomes of children treated with radiation due to the increased radiosensitivity and life-span expectations of children versus adults.
Discrepancies concerning the absolute values of the presented risk factors using the different calculation methods were apparent. However, the relative comparisons showed that the IMRT treatment modalities can reduce the risk for radiation-induced malignancies as opposed to 3D-CRT treatment delivery. The results of this study indicated that significant advantages can be attained in pediatric patients by choosing the appropriate method for radiation therapy. For pediatric patients, decreasing secondary cancer as a result of radiation therapy must be a significant factor when choosing the proper treatment modality. Although this risk is not the exclusive determinant for the course of radiation therapy, it is definitely a necessary component when deciding the most beneficial way to improve the quality of life for those treated as children.
